Beyond Air XAIR Stock
Beyond Air Price Chart
Beyond Air XAIR Financial and Trading Overview
| Beyond Air stock price | 0.44 USD |
| Previous Close | 0.46 USD |
| Open | 0.47 USD |
| Bid | 0.35 USD x 200 |
| Ask | 0.6 USD x 200 |
| Day's Range | 0.45 - 0.51 USD |
| 52 Week Range | 0.38 - 5.84 USD |
| Volume | 230.94K USD |
| Avg. Volume | 306.86K USD |
| Market Cap | 6.17M USD |
| Beta (5Y Monthly) | 0.296 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -4.47 USD |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 8 USD |
XAIR Valuation Measures
| Enterprise Value | 17.22M USD |
| Trailing P/E | N/A |
| Forward P/E | -0.29289156 |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | 0.8912743 |
| Price/Book (mrq) | 0.5038342 |
| Enterprise Value/Revenue | 2.488 |
| Enterprise Value/EBITDA | -0.668 |
Trading Information
Beyond Air Stock Price History
| Beta (5Y Monthly) | 0.296 |
| 52-Week Change | -87.074% |
| S&P500 52-Week Change | 27.29% |
| 52 Week High | 5.84 USD |
| 52 Week Low | 0.38 USD |
| 50-Day Moving Average | 0.57 USD |
| 200-Day Moving Average | 1.34 USD |
XAIR Share Statistics
| Avg. Volume (3 month) | 306.86K USD |
| Avg. Daily Volume (10-Days) | 258.63K USD |
| Shares Outstanding | 12.69M |
| Float | 10.3M |
| Short Ratio | 0.19 |
| % Held by Insiders | 3.64% |
| % Held by Institutions | 11.40% |
| Shares Short | 79.5K |
| Short % of Float | 0.64% |
| Short % of Shares Outstanding | 0.63% |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor | 1:20 |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | March 31, 2025 |
| Most Recent Quarter (mrq) | December 31, 2025 |
| Next Fiscal Year End | March 31, 2026 |
Profitability
| Profit Margin | 0% |
| Operating Margin (ttm) | -300.63% |
| Gross Margin | 1.82% |
| EBITDA Margin | 0% |
Management Effectiveness
| Return on Assets (ttm) | -51.20% |
| Return on Equity (ttm) | -240.20% |
Income Statement
| Revenue (ttm) | 6.92M USD |
| Revenue Per Share (ttm) | 1.13 USD |
| Quarterly Revenue Growth (yoy) | 104.69% |
| Gross Profit (ttm) | 126K USD |
| EBITDA | -25785000 USD |
| Net Income Avi to Common (ttm) | -31001000 USD |
| Diluted EPS (ttm) | -4.47 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 11.66M USD |
| Total Cash Per Share (mrq) | 1.11 USD |
| Total Debt (mrq) | 23.59M USD |
| Total Debt/Equity (mrq) | 284.71 USD |
| Current Ratio (mrq) | 5.124 |
| Book Value Per Share (mrq) | 0.965 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -20155000 USD |
| Levered Free Cash Flow (ttm) | -18648376 USD |
Profile of Beyond Air
| Country | United States |
| State | NY |
| City | Garden City |
| Address | 900 Stewart Avenue |
| ZIP | 11530 |
| Phone | 516 665 8200 |
| Website | https://www.beyondair.net |
| Industry | Medical Devices |
| Sector(s) | Healthcare |
| Full Time Employees | 61 |
Beyond Air, Inc., a commercial-stage medical device and biopharmaceutical company, develops the Lungfit platform, a nitric oxide (NO) generator and delivery system platform. It operates through three segments: Beyond Air, Beyond Cancer, and NeuroNos. The company offers Lungfit PH for the treatment of persistent pulmonary hypertension of the newborn. It is also developing LungFit PRO for the treatment of viral lung infections, such as community-acquired pneumonia, including COVID-19 and bronchiolitis in hospitalized patients; and LungFit GO for the treatment of nontuberculous mycobacteria (NTM) at home. In addition, the company develops ultra-high concentration (UNO) that is in Phase 1 clinical trial to treat multiple solid and cutaneous tumors; and selective neuronal nitric oxide synthase (nNOS) inhibitor for the treatment of neurological conditions and autism spectrum disorder. It has a collaboration with the Yissum Research Development Company of the Hebrew University of Jerusalem, LTD to acquire the commercial rights for neuronal nitric oxide synthase inhibitors to treat autism spectrum disorder and other neurological conditions. The company was formerly known as AIT Therapeutics, Inc. and changed its name to Beyond Air, Inc. in June 2019. Beyond Air, Inc. was founded in 2011 and is headquartered in Garden City, New York.
Q&A For Beyond Air Stock
What is a current XAIR stock price?
Beyond Air XAIR stock price today per share is 0.44 USD.
How to purchase Beyond Air stock?
You can buy XAIR shares on the Tech Market Small exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Beyond Air?
The stock symbol or ticker of Beyond Air is XAIR.
Which industry does the Beyond Air company belong to?
The Beyond Air industry is Medical Devices.
How many shares does Beyond Air have in circulation?
The max supply of Beyond Air shares is 12.69M.
What is Beyond Air Price to Earnings Ratio (PE Ratio)?
Beyond Air PE Ratio is now.
What was Beyond Air earnings per share over the trailing 12 months (TTM)?
Beyond Air EPS is -4.47 USD over the trailing 12 months.
Which sector does the Beyond Air company belong to?
The Beyond Air sector is Healthcare.
Beyond Air XAIR included in indexes
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
|---|
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
|---|---|---|---|---|---|---|---|
| {{ item.name }} {{ item.symbol }} | {{ item.price }} {{ item.price_usd }} |
{{ item.change_pct }}
|
{{ item.volume }} {{ item.volume_usd }} | {{ item.low }} {{ item.low_usd }} | {{ item.high }} {{ item.high_usd }} | {{ item.components_count }} - | {{ item.volume }} {{ item.volume_usd }} |
| US Tech Composite IXIC | 26853.98 USD — |
-0.89
|
8.32B USD — | 26769.16 USD — | 27130.88 USD — | — - | 8.32B USD — |
| US Tech Capital Market Composite RCMP | 148.96 USD — |
-1.84
|
— — | 148.23 USD — | 151.02 USD — | — - | — — |
| US Tech Health Care IXHC | 1133.51 USD — |
+1.54
|
— — | 1113.35 USD — | 1133.95 USD — | — - | — — |
- {{ link.label }} {{link}}